Skip to content

Rezafungin: Patient Guide for Invasive Candida Infections

Published: July 26, 2026Updated: July 26, 2026

Rezafungin is an antifungal medicine given through a vein (intravenous infusion). It is used in adults to treat candidemia and certain other serious infections caused by Candida yeast.

Quick summary

Rezafungin is a hospital or infusion-center treatment for serious Candida infections. It is given as an initial dose followed by another dose on day 8, and serious reactions or medication interactions should be discussed with your care team.

Medically reviewed by WellAlly Editorial TeamLast reviewed July 26, 2026Editorial policy

Key facts at a glance

RxNorm
2639155
Generic
Rezafungin
Class
unclassified
Brands
Rezzayo
Availability
rx
Lactation
unknown
Routes
—
Forms
injection
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy